Acelyrin doubles down on Alumis merger after deciding Concentra’s surprise offer 'not superior' VC firm Sofinnova brings in €1.2B over a year to fund up to 60 life sciences companies Atara, reeling from FDA hold on Ebvallo, lays off half of workforce Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin UPDATE: Biohaven's bipolar candidate fails to improve mania in pivotal trial PepGen pauses UK arm of DMD trial that's already on hold in US Fierce Biotech Fundraising Tracker '25: Garuda grabs $50M series A; Callio launches with $187M Gene therapy prevents death, restores growth in mice and a calf with maple syrup urine disease Pliant discontinues late-stage lung disease trial for lead asset after safety review | 